FDA Approves NUMELVI for Dogs from Merck Animal Health - The First and Only Second-Generation Janus Kinase Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir , an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
Merck Announces Positive New Data for ENFLONSIA for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus Disease Over Two RSV Seasons
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
Health Canada Approves KEYTRUDA SC, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Health Canada Approves KEYTRUDA SC, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Health Canada Approves KEYTRUDA SC, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Earthwise Announces Planning Underway for 1,000 Meter Drill Program at Talon Zone, Iron Range Gold Project, BC
